Related Experiment Video

Updated: Mar 9, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Onartuzumab ineffective in non-small-cell lung cancer

Vicki Brower

    The Lancet. Oncology
    |December 27, 2016
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
    07:43

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

    Published on: September 25, 2018

    11.1K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Related Experiment Videos

    Last Updated: Mar 9, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    11.1K
    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
    07:43

    Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

    Published on: September 25, 2018

    11.1K
    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
    10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    11.2K

    Related Concept Videos

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    701
    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
    701

    Articles linked to this work by shared authors, journal, and citation graph.

    Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

    The Lancet. Oncology·2026

    Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

    The Lancet. Oncology·2026

    Advancing oncology education in low-income and middle-income African settings: global insights for local action.

    The Lancet. Oncology·2026

    Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

    The Lancet. Oncology·2026

    Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

    The Lancet. Oncology·2026

    Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

    The Lancet. Oncology·2026

    Impact of omitting contralateral systematic biopsy on clinically significant upgrading at radical prostatectomy: a retrospective paired-design study.

    International urology and nephrology·2026

    Unrecognized primary aldosteronism may confound outcomes in adrenal Cushing's syndrome.

    Therapeutic advances in endocrinology and metabolism·2026

    Atypical notochordal cell tumors: an alternative diagnosis when diagnostic criteria are not straightforward : Short title: atypical notochordal cell tumor.

    Virchows Archiv : an international journal of pathology·2026

    Survival Outcomes With Concurrent Systemic Therapy in Patients With a Medical Contraindication to Cisplatin in the Non-Operative Management of Locally Advanced HNSCC, an NCDB Study.

    Head & neck·2026

    Lung Cancer in Never Smokers-An Underappreciated Public Health Burden.

    Health science reports·2026

    Clinicopathologic features of colorectal gastric heterotopia.

    Annals of diagnostic pathology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us